Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVAC-2 booster in healthy adults
NCT05226702Phase 1Completed
- Sponsor
- University of Saskatchewan
- Start
- Jul 2022
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of COVAC-2 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by University of Saskatchewan. Primary endpoint: Assessment of the safety and tolerability of COVAC-2 booster vaccine at 365 days. Started Jul 2022; status: completed.
02
Drugs
COVAC-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05226702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226702.